SCHEMBL4877273

SCHEMBL4877273

Cc1nc(C)c(-c2ccc3cc(-c4c(C5CCCCC5)c5sc(C(=O)O)cc5n4CC(=O)N4CCC(N5CCCC5)CC4)ccc3n2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.40
GAA P10253 2/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37
HRH3 Q9Y5N1 2/20 0.37
KCNH2 Q12809 1/20 0.37
LMNA P02545 1/20 0.35
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
G6PD P11413 1/20 0.34
HPGD P15428 1/20 0.34
CACNA1B Q00975 1/20 0.34
APBA1 Q02410 1/20 0.34
HSD17B10 Q99714 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CBX7 O95931 3/20 0.33
CDYL2 Q8N8U2 3/20 0.33
CDYL Q9Y232 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4874701 0.95 TP53 (0.36) TP53GAAPOLBTSHRHRH3
SCHEMBL4876216 0.95 KCNH2 (0.39) TP53GAAHRH3KCNH2ALDH1A1
SCHEMBL4874030 0.95 KCNH2 (0.39) TP53GAAHRH3KCNH2ALDH1A1
SCHEMBL4876338 0.93 KCNH2 (0.39) TP53GAAHRH3KCNH2ALDH1A1
SCHEMBL4868308 0.93 KCNH2 (0.38) TP53GAAHRH3KCNH2LMNA
SCHEMBL3938006 0.91 KCNH2 (0.38) TP53GAATSHRHRH3KCNH2
SCHEMBL4878251 0.91 KCNH2 (0.38) TP53GAAHRH3KCNH2ALDH1A1
SCHEMBL3931408 0.91 KCNH2 (0.37) TP53GAAHRH3KCNH2MAPT
SCHEMBL4874551 0.90 KCNH2 (0.36) TP53HRH3KCNH2CBX7CDYL2
SCHEMBL4877163 0.90 KCNH2 (0.39) GAAHRH3KCNH2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 TP53 3049/4885GAA 66/4885POLB 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.